METOPROLOL SUCCINATE EXTENDED RELEASE

Metoprolol Succinate Extended Release Adverse Events Reported to the FDA Over Time

How are Metoprolol Succinate Extended Release adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Metoprolol Succinate Extended Release, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Metoprolol Succinate Extended Release is flagged as the suspect drug causing the adverse event.

Most Common Metoprolol Succinate Extended Release Adverse Events Reported to the FDA

What are the most common Metoprolol Succinate Extended Release adverse events reported to the FDA?

Dizziness	31 (3.51%)
Product Quality Issue	29 (3.28%)
Blood Pressure Increased	28 (3.17%)
Palpitations	28 (3.17%)
Heart Rate Increased	21 (2.38%)
Product Substitution Issue	19 (2.15%)
Fatigue	16 (1.81%)
Therapeutic Response Unexpected Wit...	16 (1.81%)
Dyspnoea	15 (1.7%)
Drug Ineffective	14 (1.59%)
Insomnia	14 (1.59%)
	Show More
Completed Suicide	12 (1.36%)
Headache	12 (1.36%)
Anxiety	11 (1.25%)
Nausea	11 (1.25%)
Chest Pain	10 (1.13%)
Heart Rate Decreased	10 (1.13%)
Malaise	10 (1.13%)
Oedema Peripheral	10 (1.13%)
Asthenia	9 (1.02%)
Blood Pressure Inadequately Control...	9 (1.02%)
Heart Rate Irregular	9 (1.02%)
Hypoaesthesia	9 (1.02%)
Hyperhidrosis	8 (.91%)
Hypertension	8 (.91%)
Bradycardia	7 (.79%)
Chest Discomfort	7 (.79%)
Diarrhoea	7 (.79%)
Extrasystoles	7 (.79%)
Feeling Abnormal	7 (.79%)
Hypotension	7 (.79%)
Overdose	7 (.79%)
Pain In Extremity	7 (.79%)
Poisoning	7 (.79%)
Suicide Attempt	7 (.79%)
Concomitant Disease Progression	6 (.68%)
Condition Aggravated	6 (.68%)
Depression	6 (.68%)
Paraesthesia	6 (.68%)
Peripheral Coldness	6 (.68%)
Syncope	6 (.68%)
Vomiting	6 (.68%)
Abdominal Pain Upper	5 (.57%)
Blood Pressure Fluctuation	5 (.57%)
Drug Effect Decreased	5 (.57%)
Dyspepsia	5 (.57%)
Gait Disturbance	5 (.57%)
Vision Blurred	5 (.57%)
Weight Increased	5 (.57%)
Angina Unstable	4 (.45%)
Burning Sensation	4 (.45%)
Confusional State	4 (.45%)
Cough	4 (.45%)
Incorrect Dose Administered	4 (.45%)
Medication Error	4 (.45%)
Muscle Spasms	4 (.45%)
Myocardial Infarction	4 (.45%)
Pain	4 (.45%)
Rash	4 (.45%)
Rash Pruritic	4 (.45%)
Suicidal Ideation	4 (.45%)
Tinnitus	4 (.45%)
Tremor	4 (.45%)
Alopecia	3 (.34%)
Arrhythmia	3 (.34%)
Blood Pressure Decreased	3 (.34%)
Blood Pressure Diastolic Decreased	3 (.34%)
Cardiac Arrest	3 (.34%)
Death	3 (.34%)
Dysgeusia	3 (.34%)
Exercise Tolerance Decreased	3 (.34%)
Hypersensitivity	3 (.34%)
Influenza	3 (.34%)
Loss Of Consciousness	3 (.34%)
Mental Impairment	3 (.34%)
Oedema	3 (.34%)
Off Label Use	3 (.34%)
Presyncope	3 (.34%)
Sinus Bradycardia	3 (.34%)
Stomatitis	3 (.34%)
Stress	3 (.34%)
Tachycardia	3 (.34%)
Thinking Abnormal	3 (.34%)
Ventricular Extrasystoles	3 (.34%)
Abdominal Discomfort	2 (.23%)
Abnormal Dreams	2 (.23%)
Anger	2 (.23%)
Apparent Death	2 (.23%)
Arthralgia	2 (.23%)
Atrial Fibrillation	2 (.23%)
Balance Disorder	2 (.23%)
Blood Albumin Decreased	2 (.23%)
Blood Glucose Increased	2 (.23%)
Blood Pressure Abnormal	2 (.23%)
Blood Sodium Decreased	2 (.23%)
Cardiac Disorder	2 (.23%)
Cardiac Failure Congestive	2 (.23%)
Circumstance Or Information Capable...	2 (.23%)
Crying	2 (.23%)
Disorientation	2 (.23%)
Drug Dispensing Error	2 (.23%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Metoprolol Succinate Extended Release, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Metoprolol Succinate Extended Release is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Metoprolol Succinate Extended Release

What are the most common Metoprolol Succinate Extended Release adverse events reported to the FDA?

Cardiac And Vascular Investigations	85 (9.63%)
Neurological	76 (8.61%)
Product Quality Issues	56 (6.34%)
Therapeutic And Nontherapeutic Effe...	40 (4.53%)
Cardiac Arrhythmias	39 (4.42%)
Gastrointestinal Signs	33 (3.74%)
Cardiac Disorder Signs	32 (3.62%)
Respiratory	29 (3.28%)
Medication Errors	24 (2.72%)
Decreased And Nonspecific Blood Pre...	23 (2.6%)
Suicidal And Self-injurious Behavio...	23 (2.6%)
	Show More
Anxiety Disorders	21 (2.38%)
Epidermal And Dermal Conditions	21 (2.38%)
Sleep Disorders	17 (1.93%)
Headaches	14 (1.59%)
Skin Appendage Conditions	13 (1.47%)
Musculoskeletal And Connective Tiss...	10 (1.13%)
Gastrointestinal Motility And Defec...	9 (1.02%)
Vascular Hypertensive	9 (1.02%)
Coronary Artery	8 (.91%)
Vision	8 (.91%)
Chemical Injury And Poisoning	7 (.79%)
Depressed Mood Disorders	7 (.79%)
Disturbances In Thinking	7 (.79%)
Mental Impairment	7 (.79%)
Arteriosclerosis, Stenosis, Vascula...	6 (.68%)
Deliria	6 (.68%)
Inner Ear And Viiith Cranial Nerve	6 (.68%)
Joint	6 (.68%)
Muscle	6 (.68%)
Physical Examination Topics	6 (.68%)
Water, Electrolyte And Mineral	6 (.68%)
Hepatic And Hepatobiliary	5 (.57%)
Oral Soft Tissue Conditions	5 (.57%)
Appetite And General Nutritional	4 (.45%)
Electrolyte And Fluid Balance Condi...	4 (.45%)
Eye	4 (.45%)
Injuries	4 (.45%)
Lifestyle Issues	4 (.45%)
Mood Disorders	4 (.45%)
Movement Disorders	4 (.45%)
Viral Infectious	4 (.45%)
Allergic Conditions	3 (.34%)
Economic And Housing Issues	3 (.34%)
Fatal Outcomes	3 (.34%)
Glucose Metabolism Disorders	3 (.34%)
Heart Failures	3 (.34%)
Hematology Investigations	3 (.34%)
Hepatobiliary	3 (.34%)
Metabolic, Nutritional And Blood Ga...	3 (.34%)
Protein And Chemistry Analyses	3 (.34%)
Therapeutic Procedures And Supporti...	3 (.34%)
Bronchial Disorders	2 (.23%)
Gastrointestinal Conditions	2 (.23%)
Gastrointestinal Hemorrhages	2 (.23%)
Infections - Pathogen Unspecified	2 (.23%)
Lower Respiratory Tract Disorders	2 (.23%)
Ocular Neuromuscular	2 (.23%)
Salivary Gland Conditions	2 (.23%)
Sleep Disturbances	2 (.23%)
Urinary Tract Signs	2 (.23%)
Vascular	2 (.23%)
Abdominal Hernias And Other Abdomin...	1 (.11%)
Acid-base	1 (.11%)
Administration Site Reactions	1 (.11%)
Angiedema And Urticaria	1 (.11%)
Breast Neoplasms Benign	1 (.11%)
Central Nervous System Vascular	1 (.11%)
Diverticular	1 (.11%)
Enzyme	1 (.11%)
Fetal And Neonatal	1 (.11%)
Gastrointestinal Ulceration And Per...	1 (.11%)
Hematological And Lymphoid Tissue T...	1 (.11%)
Injuries By Physical Agents	1 (.11%)
Lipid Metabolism	1 (.11%)
Menstrual Cycle And Uterine Bleedin...	1 (.11%)
Metastases	1 (.11%)
Peripheral Neuropathies	1 (.11%)
Psychiatric And Behavioural Symptom...	1 (.11%)
Renal Disorders	1 (.11%)
Seizures	1 (.11%)
Tissue	1 (.11%)
Tongue Conditions	1 (.11%)
Upper Respiratory Tract Disorders	1 (.11%)
Vulvovaginal Disorders	1 (.11%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Metoprolol Succinate Extended Release, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Metoprolol Succinate Extended Release is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.